MartÃnez Picado, Javier
Research Professor
Life & Medical Sciences
Institucio Catalana de Recerca i Estudis Avancats
Spain
Biography
Javier Martínez-Picado is ICREA Research Professor at the AIDS Research Institute irsiCaixa in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the Autonomous University of Barcelona and the University of Vic. He received his PhD from the University of Barcelona where he subsequently became associate professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of the Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hospital "Germans Trias i Pujol" in Badalona (Barcelona). Dr. Martínez-Picado serves on different government, academic and industry advisory boards and has published extensively on HIV treatment strategies and HIV pathogenesis in international journals.
Research Interest
The main subject of our biomedical research is the Human Immunodeficiency Virus (HIV), a retrovirus that can lead to Acquired ImmunoDeficiency Syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. In 2015, 1.1 million people died from AIDS-related causes and 2.1 million became newly infected worldwide. Our research programmes are focused on understanding how HIV causes disease in recently infected people, exploring the best antiretroviral therapies, fighting drug resistance, exploring potential virus eradication strategies and collaborating on global HIV/AIDS vaccine development projects.
Publications
-
Hancock G, Morón-López S, Kopycinski J, Puertas MC, Giannoulatou E, Rose A, Salgado M, Hayton E-J, Crook A, Morgan C, Angus B, Chen F, Yang H, Martinez-Picado J, Hanke T, Dorrell L 2017. 'Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects'. Journal of the International AIDS Society, vol. 20, pp 21171.
-
Minuesa G, Albert C, Pastor-Anglada M, Martinez-Picado J, Koepsell H 2017, 'Response to the Letter of H. Shen, W.Li, W.G. Humphreys and Y. Lai with the Title: Tenofovir Disoproxil Fumarate (TDF) is not an Inhibitor of Human Organic Cation Transporter 1 (OCT1)'. The Journal of Pharmacology and Experimental Therapeutics, 360:343–5.
-
Morón-López S, Puertas MC, Gálvez C, Navarro J, Carrasco A, Esteve M, Manyé J, Crespo M, Salgado M, Martinez-Picado J 2017, 'Sensitive Quantification of the HIV-1 Reservoir in Gut-Associated Lymphoid Tissue', PLoS One 12(4):e0175899.